(Q43133978)

14 November 2017

title

Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma (English)

1 reference

14 November 2017

1 reference

Oleksandr Ekshyyan

1

1 reference

14 November 2017

Glenn M Mills

2

1 reference

14 November 2017

Timothy Lian

3

1 reference

14 November 2017

Nazanin Amirghahari

4

1 reference

14 November 2017

Xiaohua Rong

5

1 reference

14 November 2017

Mary Lowery-Nordberg

6

1 reference

14 November 2017

Fleurette Abreo

7

1 reference

14 November 2017

Diana M Veillon

8

1 reference

14 November 2017

Gloria Caldito

9

1 reference

14 November 2017

Lisa Speicher

10

1 reference

14 November 2017

Jonathan Glass

11

1 reference

14 November 2017

Cherie-Ann O Nathan

12

1 reference

14 November 2017

publication date

1 December 2010

1 reference

14 November 2017

1 reference

14 November 2017

volume

32

1 reference

14 November 2017

issue

12

1 reference

14 November 2017

page(s)

1619-1628

1 reference

Loss of PTEN expression as a prognostic marker for tongue cancer

14 November 2017

cites work

1 reference

Molecular mediators of metastasis in head and neck squamous cell carcinoma

21 January 2018

1 reference

7 January 2021

A vision for the National Cancer Program in the United States.

1 reference

7 January 2021

Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01.

1 reference

7 January 2021

Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway

1 reference

7 January 2021

Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer

1 reference

7 January 2021

Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer

1 reference

7 January 2021

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

1 reference

7 January 2021

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

1 reference

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

7 January 2021

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

1 reference

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

7 January 2021

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

1 reference

7 January 2021

Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha

1 reference

7 January 2021

Clinical development of mammalian target of rapamycin inhibitors

1 reference

7 January 2021

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

1 reference

7 January 2021

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

1 reference

7 January 2021

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

1 reference

7 January 2021

Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family

1 reference

7 January 2021

Regulation of peptide-chain elongation in mammalian cells

1 reference

7 January 2021

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

1 reference

7 January 2021

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

7 January 2021

Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase.

1 reference

7 January 2021

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

7 January 2021

Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma

1 reference

7 January 2021

The phosphoinositide 3-kinase pathway

1 reference

7 January 2021

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

7 January 2021

Will mTOR inhibitors make it as cancer drugs?

1 reference

7 January 2021

Identifiers

DOI

10.1002/HED.21374

1 reference

14 November 2017

1 reference